Skip to content

Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial

Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02447029
Acronym
SALSA
Enrollment
142
Registered
2015-05-18
Start date
2015-04-30
Completion date
2016-01-31
Last updated
2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Unwanted

Keywords

abortion, pain management

Brief summary

Despite global efforts to decrease discomfort during surgical abortion, pain remains a limiting factor in where and how procedures are performed. Several studies have investigated different methods of delivering cervical anesthesia prior to abortion, however to the best of the investigators' knowledge, there is no published data that 1) rigorously examines the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explores whether adequate pain relief is possible through self-administered, non-invasive means alone. Research in this area has a significant public health impact, given the large number of women worldwide who seek abortions. The investigators propose to explore the effect of a locally applied vaginal lidocaine gel in place of the traditional paracervical block prior to first trimester surgical abortion. They hypothesize that lidocaine gel is no worse than paracervical block at decreasing abortion related pain at a variety of time points throughout the procedure. This is a non-inferiority, open label, randomized controlled trial. If self-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures.

Detailed description

Abortion remains one of the most common surgical procedures in the world, regardless of region or development status \[Guttmacher 2012\]. In the United States, at least half of all women will experience an unintended pregnancy by age 45, and one third of all women will have had an abortion by this same age \[Guttmacher 2014\]. Despite universal efforts to increase the comfort of these procedures, pain remains a limiting factor in where and how abortion is performed. Recent estimates reveal that 70-97% of women experience pain during abortion \[Renner 2010, Paul 2009, Belanger 1988\]. Strategies to reduce all aspects of abortion related pain have the potential for significant public health impact, given the large number of women who seek these services. A survey of National Abortion Federation clinics found that to date, most providers (84%) employ the use of a lidocaine paracervical block for cervical anesthesia prior to abortion \[O'Connell 2009\], but traditionally without a waiting period between lidocaine administration and procedure initiation. To the best of our knowledge, there are no published studies that 1) rigorously examine the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explore whether adequate pain relief is possible through self-administered, non-invasive means alone. The investigators propose to explore the effect of a locally applied lidocaine gel in place of the traditional paracervical block to decrease abortion related pain. The objective of this study is to compare pain control at various time points during first trimester surgical abortion using a locally applied, patient-administered lidocaine gel as compared to traditional lidocaine paracervical block. If a patient-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures, and perhaps replace paracervical injection altogether. Hypothesis: Patients who receive lidocaine gel applied 30 minutes prior to first trimester surgical abortion will have pain control equivalent to that of a traditional paracervical block. This is a non-inferiority, open-label, randomized controlled trial of women ages 18 and older undergoing first trimester surgical abortion at 50/7 to 116/7 weeks.

Interventions

DRUGvaginal 2% Xylocaine

patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block

DRUGstandard lidocaine paracervical block

1% lidocaine paracervical injection

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women ages 18 and older undergoing elective surgical abortion at 5 and 0/7 to 11 and 6/7 weeks gestational age * Use of IV sedation for pain management * English or Spanish speaking * Ability to give informed consent

Exclusion criteria

* Any pre-operative use of misoprostol (typically given at 12 weeks and above in this clinic) * Allergy to study medications: lidocaine, midazolam, fentanyl * Known uterine anomaly * Prior cervical surgery.

Design outcomes

Primary

MeasureTime frameDescription
Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog ScaleAt time of cervical dilation, 30 minutes after lidocaine administrationThis is the amount of pain self-reported by the patient at the time of cervical dilation. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Secondary

MeasureTime frameDescription
Pain With Speculum Insertion as Measured by a Visual Analog ScalePain at time of speculum insertionThis is the amount of pain self-reported by the patient at the time of speculum insertion. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.
Pain With Tenaculum Placement as Measured by a Visual Analog ScalePain at time of tenaculum placementThis is the amount of pain self-reported by the patient at the time of tenaculum placement. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.
Pain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog ScalePain level prior to procedureThis is the amount of pain self-reported by the patient prior to the procedure (Anticipated pain). VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.
Overall Satisfaction With Procedure as Measured by a Visual Analog Scale30-45 minutes after completion of procedureThis is the level of overall satisfaction self-reported by the patient at the completion of the procedure and prior to discharge. VAS ranged from 0 to 100 mm, 0 equals not satisfied, 100 equals highest satisfaction possible.
Overall Complication Rate as Measured by a Count of Participants in Each GroupRate of complications at the end of the study
Pain 30-45 Minutes After Procedure as Measured by a Visual Analog ScalePain prior to discharge home: 30-45 minutes after completion of procedureThis is the amount of pain self-reported by the patient 30-45 minutes after procedure. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Countries

United States

Participant flow

Participants by arm

ArmCount
Active Comparator
Drug: vaginal 2% Xylocaine vaginal 2% Xylocaine: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
69
Standard Lidocaine Paracervical Block
standard lidocaine paracervical block standard lidocaine paracervical block: 1% lidocaine paracervical injection
68
Total137

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject32

Baseline characteristics

CharacteristicActive ComparatorStandard Lidocaine Paracervical BlockTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
69 Participants68 Participants137 Participants
Sex: Female, Male
Female
69 Participants68 Participants137 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 690 / 68
serious
Total, serious adverse events
0 / 690 / 68

Outcome results

Primary

Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale

This is the amount of pain self-reported by the patient at the time of cervical dilation. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Time frame: At time of cervical dilation, 30 minutes after lidocaine administration

Population: Treated participants were included in the analysis.

ArmMeasureValue (MEDIAN)
Active ComparatorDifference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale68 units on a scale
Standard Lidocaine Paracervical BlockDifference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale65 units on a scale
Secondary

Overall Complication Rate as Measured by a Count of Participants in Each Group

Time frame: Rate of complications at the end of the study

Population: All treated patients were analyzed

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Active ComparatorOverall Complication Rate as Measured by a Count of Participants in Each Group0 Participants
Standard Lidocaine Paracervical BlockOverall Complication Rate as Measured by a Count of Participants in Each Group0 Participants
Secondary

Overall Satisfaction With Procedure as Measured by a Visual Analog Scale

This is the level of overall satisfaction self-reported by the patient at the completion of the procedure and prior to discharge. VAS ranged from 0 to 100 mm, 0 equals not satisfied, 100 equals highest satisfaction possible.

Time frame: 30-45 minutes after completion of procedure

Population: All treated patients were included in the analysis

ArmMeasureValue (MEDIAN)
Active ComparatorOverall Satisfaction With Procedure as Measured by a Visual Analog Scale86 units on a scale
Standard Lidocaine Paracervical BlockOverall Satisfaction With Procedure as Measured by a Visual Analog Scale92.5 units on a scale
Secondary

Pain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale

This is the amount of pain self-reported by the patient 30-45 minutes after procedure. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Time frame: Pain prior to discharge home: 30-45 minutes after completion of procedure

Population: All treated patients were included in the analysis

ArmMeasureValue (MEDIAN)
Active ComparatorPain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale9 units on a scale
Standard Lidocaine Paracervical BlockPain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale11.5 units on a scale
Secondary

Pain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale

This is the amount of pain self-reported by the patient prior to the procedure (Anticipated pain). VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Time frame: Pain level prior to procedure

Population: Treated patients were included in the analysis

ArmMeasureValue (MEDIAN)
Active ComparatorPain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale59 units on a scale
Standard Lidocaine Paracervical BlockPain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale56 units on a scale
Secondary

Pain With Speculum Insertion as Measured by a Visual Analog Scale

This is the amount of pain self-reported by the patient at the time of speculum insertion. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Time frame: Pain at time of speculum insertion

Population: Treated patients were included in the analysis

ArmMeasureValue (MEAN)Dispersion
Active ComparatorPain With Speculum Insertion as Measured by a Visual Analog Scale19.5 units on a scaleStandard Deviation 18.4
Standard Lidocaine Paracervical BlockPain With Speculum Insertion as Measured by a Visual Analog Scale22.3 units on a scaleStandard Deviation 19.5
Secondary

Pain With Tenaculum Placement as Measured by a Visual Analog Scale

This is the amount of pain self-reported by the patient at the time of tenaculum placement. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Time frame: Pain at time of tenaculum placement

Population: All treated patients were included in the analysis

ArmMeasureValue (MEAN)Dispersion
Active ComparatorPain With Tenaculum Placement as Measured by a Visual Analog Scale39.8 units on a scaleStandard Deviation 22.3
Standard Lidocaine Paracervical BlockPain With Tenaculum Placement as Measured by a Visual Analog Scale32.4 units on a scaleStandard Deviation 24.3

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026